Rogco LP Has $916,000 Holdings in Merck & Co., Inc. (NYSE:MRK)

Rogco LP trimmed its holdings in Merck & Co., Inc. (NYSE:MRK) by 7.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,068 shares of the company’s stock after selling 670 shares during the period. Rogco LP’s holdings in Merck & Co., Inc. were worth $916,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Itau Unibanco Holding S.A. acquired a new position in shares of Merck & Co., Inc. in the second quarter valued at $39,000. Abich Financial Wealth Management LLC lifted its holdings in Merck & Co., Inc. by 121.8% during the 2nd quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock worth $40,000 after purchasing an additional 179 shares during the last quarter. Quarry LP bought a new position in Merck & Co., Inc. during the 2nd quarter worth $42,000. Strategic Financial Concepts LLC grew its stake in shares of Merck & Co., Inc. by 1,475.6% in the second quarter. Strategic Financial Concepts LLC now owns 35,057 shares of the company’s stock valued at $43,000 after acquiring an additional 32,832 shares in the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC boosted its holdings in Merck & Co., Inc. by 47.5% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 379 shares of the company’s stock valued at $43,000 after purchasing an additional 122 shares during the period. 76.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

MRK has been the subject of several recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price objective on shares of Merck & Co., Inc. in a research report on Thursday, October 3rd. Truist Financial decreased their price objective on shares of Merck & Co., Inc. from $143.00 to $132.00 and set a “buy” rating on the stock in a research note on Wednesday, October 9th. Sanford C. Bernstein began coverage on Merck & Co., Inc. in a research note on Thursday, October 17th. They set a “market perform” rating and a $115.00 target price for the company. Evercore ISI upgraded Merck & Co., Inc. to a “strong-buy” rating in a research note on Tuesday, July 30th. Finally, Barclays dropped their target price on shares of Merck & Co., Inc. from $142.00 to $140.00 and set an “overweight” rating for the company in a report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, nine have given a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, Merck & Co., Inc. has an average rating of “Moderate Buy” and an average target price of $131.62.

Merck & Co., Inc. Trading Down 0.8 %

Shares of NYSE MRK traded down $0.89 during trading on Thursday, reaching $105.49. The company had a trading volume of 2,333,648 shares, compared to its average volume of 8,762,497. Merck & Co., Inc. has a 12 month low of $99.80 and a 12 month high of $134.63. The company has a quick ratio of 1.22, a current ratio of 1.47 and a debt-to-equity ratio of 0.80. The stock has a market cap of $267.19 billion, a P/E ratio of 117.92, a PEG ratio of 1.55 and a beta of 0.39. The company’s fifty day moving average price is $113.86 and its 200-day moving average price is $121.93.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, July 30th. The company reported $2.28 EPS for the quarter, beating the consensus estimate of $2.16 by $0.12. Merck & Co., Inc. had a return on equity of 40.69% and a net margin of 21.99%. The business had revenue of $16.10 billion for the quarter, compared to analysts’ expectations of $15.87 billion. During the same period in the prior year, the business posted ($2.06) earnings per share. The firm’s revenue was up 7.1% on a year-over-year basis. As a group, research analysts expect that Merck & Co., Inc. will post 7.88 earnings per share for the current year.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.